Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer

Torrisi, Rosalba; Montagna, Emilia; Scarano, Eloise; Dellapasqua, Silvia; Cancello, Giuseppe; Iorfida, Monica; Luini, Alberto; Veronesi, Paolo; Viale, Giuseppe; Goldhirsch, Aron; Colleoni, Marco

doi:10.1016/j.breast.2010.06.005

« Previous Next »The Breast
Volume 20, Issue 1 , Pages 34-38, February 2011

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer

Rosalba Torrisi
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Corresponding author. Present address: Department of Oncology and Hematology, Istituto Clinico Humanitas, Viale A. Manzoni 56, 20089 Rozzano, Milano, Italy. Tel.: +39 02 82244502; fax: +39 02 82244590.
Emilia Montagna
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Eloise Scarano
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Silvia Dellapasqua
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Giuseppe Cancello
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Monica Iorfida
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Alberto Luini
- Division of Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Paolo Veronesi
- Division of Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milano, Italy
Giuseppe Viale
- Division of Pathology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milano, Italy
Aron Goldhirsch
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
Marco Colleoni
- Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy
- Department of Medicine, European Institute of Oncology, via Ripamonti 435 20141 Milano, Italy

Received 10 March 2010; received in revised form 12 May 2010; accepted 15 June 2010. published online 20 July 2010.

Abstract

Purpose

To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer.

Methods

The combination of PLD with cisplatin and infusional fluorouracil (CCF) for 8 courses was investigated in patients with primary or recurrent T2-T4a-d N0-3 M0 breast cancer. Patients with ER and/or PgR ≥10% tumors also received letrozole (±triptorelin).

Results

Forty patients entered the study. Four patients had recurrent tumors and 13 had cT4d tumors. Overall, clinical response rate was 77.5% whereas a pathological complete response (pCR) was obtained in 3 patients (7.7%), 4 when considering bilateral tumors. Noticeably 3 pCR were observed among the 10 patients with T4d ER positive tumors (33%). Eleven patients discontinued treatment before completion of the 8 planned courses.

Conclusions

Our results indicated that CCF yielded an appreciable rate of clinical responses in a series of very locally advanced tumors and an unusually high rate of pCR in T4d ER positive tumors, suggesting an enhanced cutaneous activity of PLD.

Keywords: Pegylated liposomal doxorubicin, Primary therapy, Breast cancer, Inflammatory breast cancer